Bio-Rad Reports Fourth-Quarter And Full-Year 2020 Financial Results.
Q4 NON-GAAP EARNINGS PER SHARE $4.01.
Q4 EARNINGS PER SHARE $27.81.
Q4 SALES $789.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $686.8 MILLION.
FOR 2021, ANTICIPATES NON-GAAP CURRENCY-NEUTRAL REVENUE GROWTH OF ABOUT 4.5 TO 5.0%.
SEES 2021 ESTIMATED NON-GAAP OPERATING MARGIN OF ABOUT 16.0% TO 16.5%.
